The leading foreign investor in the Chinese company embroiled in a legal spat with Morgan Stanley over derivatives is Goldman Sachs, the US investment bank’s arch rival.

Morgan Stanley and China Haisheng Juice Holdings are battling in English and Chinese courts over a disputed hedging contract.